Alphatec Holdings, Inc. Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference
CARLSBAD, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. ("Alphatec" or the "Company") (Nasdaq:ATEC), a provider of innovative spine surgery solutions with a mission to improve patient lives through the relentless pursuit of superior outcomes, today announced it will present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017, at 12:30 P.M. EDT. The conference is sponsored by H.C. Wainwright & Co., LLC, and is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Terry Rich, CEO of Alphatec, will provide an overview of the Company's business during the live presentation. Management will also be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
|Event:||19th Annual Rodman & Renshaw Global Investment Conference|
|Date:||September 11, 2017|
|Time:||12:30 p.m. (Eastern Time)|
|Location:||Adams Room; Lotte New York Palace Hotel in New York City|
A copy of the presentation will be available online from the investor relations page of the Company's corporate website at www.alphatecspine.com. The conference will be webcast live. To access the webcast, please visit www.rodmanevents.com. The webcast replay will remain available for 90 days following the live presentation.
About Alphatec Holdings, Inc.
Alphatec Holdings, Inc., through its wholly owned subsidiary Alphatec Spine, Inc., is a medical device company that designs, develops, and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The Company's mission is to improve lives by providing innovative spine surgery solutions through the relentless pursuit of superior outcomes. The Company markets its products in the U.S. via independent sales agents and a direct sales force.
Additional information can be found at www.alphatecspine.com.
Statements made in this press release and made during the investor events referenced herein may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include the references to the Company's strategy in significantly repositioning the Alphatec brand and turning the Company into a growth organization. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the Company's pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community, including Battalion and Arsenal Deformity; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement for procedures performed using the Company's products; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; the Company's ability to compete with other competing products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any litigation in which the Company is a defendant; patent infringement claims; claims related to the Company's intellectual property and the Company's ability to meet its financial obligations under its credit agreements and the Orthotec settlement agreement. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and periodic reports, filed with the Securities and Exchange Commission. Alphatec disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
Investor/Media Contact: Zack Kubow The Ruth Group (646) 536-7000 email@example.com Company Contact: Jeff Black Executive Vice President and Chief Financial Officer Alphatec Holdings, Inc. (760) 431-9286 firstname.lastname@example.org